Login to Your Account



Innate Pharma, Novo Nordisk Partnering On NK Cell Biology

By James Etheridge


Wednesday, April 12, 2006
PARIS - Innate Pharma SAS and the Danish pharmaceutical company Novo Nordisk A/S entered into a strategic partnership to develop new drugs targeting natural killer (NK) cells for the treatment of cancer, autoimmune disorders and infectious diseases. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription